title: [FDG-PET in Hodgkin lymphoma].
abstract: The high negative predictive value of FDG-PET in therapy control of Hodgkin lymphoma is proven by the data acquired up to now. Thus, the analysis of the HD15 trial has shown that consolidation radiotherapy might be omitted in PET negative patients after effective chemotherapy. Further response adapted therapy guided by PET seems to be a promising approach in reducing the toxicity for patients undergoing chemotherapy. The criteria used for the PET interpretation have been standardized by the German study groups for Hodgkin lymphoma patients and will be reevaluated in the current studies.
authors.affiliation: Klinik und Poliklinik für Nuklearmedizin, Universität zu Köln, Kerpener Str. 62, 50937 Köln, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Kobe
authors.forename: M
authors.initials: M
authors.lastname: Dietlein
authors.forename: C
authors.initials: C
authors.lastname: Mauz-Körholz
authors.forename: A
authors.initials: A
authors.lastname: Engert
authors.forename: P
authors.initials: P
authors.lastname: Borchmann
authors.forename: O
authors.initials: O
authors.lastname: Sabri
authors.forename: O
authors.initials: O
authors.lastname: Schober
authors.forename: H
authors.initials: H
authors.lastname: Schicha
authors.forename: R
authors.initials: R
authors.lastname: Kluge
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019788:Fluorodeoxyglucose F18; D006689:Hodgkin Disease / Q000000981:diagnostic imaging* / Q000188:drug therapy; D006801:Humans; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18